Peter Corr, Ph.D.

Executive Chairman

Peter Corr

Dr. Corr, a pharmaceutical industry veteran of more than 26 years, will guide the company as it completes a private financing underway and advances its clinical programs using antimicrobial Bisphosphocins™ for the treatment of serious infections of the lungs, bladder, skin and other tissues, including those caused by antibiotic-resistant bacteria, yeast and fungi.


Dr. Corr, who until December 2006, served as Senior Vice President for Science and Technology of Pfizer Inc. and led worldwide pharmaceutical research and development for Pfizer, previously served as Executive Vice President, Pfizer Global Research & Development and President, Worldwide Development. He also served as Senior Vice President, Discovery Research at Monsanto/Searle and then President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.


Dr. Corr is Co-Founder and Managing General Partner of Auven Therapeutics Management LLLP. and was Chairman of the Board of Directors for ADC Therapeutics, S.A., founded by Auven, from its inception in 2011 through the completion of its upsized $267 million initial public offering in May 2020. Dr. Corr is Founder and Chairman of the Board of Imvax Inc., a research and development company focused on cancer with an initial emphasis on glioblastoma and other solid tumors.


In addition, Dr. Corr has served as Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group for six years, representing Chief Scientific Officers (CSO’s) across the European and U.S. based pharmaceutical industry. He is a former Governor of the New York Academy of Sciences (and previous Chairman of the Board of Governors). Additionally, he was Chairman of the Board of the International Partnership for Microbiocides and Chairman of the Board of Directors for the Critical Path Institute. He served as a founding member of the Board of Directors of Furiex Pharmaceuticals, Inc., until the sale of the company in 2014. He is a Founder and Chairman Emeritus of the Board of Patient Assist VI which provides medicines to indigent patients in the U.S. Virgin Islands. He currently serves on the National Council for Washington University School of Medicine.


Dr. Corr received his doctorate from Georgetown University School of Medicine and spent 18 years as a researcher in molecular biology and pharmacology at Washington University, St. Louis, ultimately becoming Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts. Dr. Corr is the recipient of numerous awards and honors.